Clinical and mechanistic study on treatment of perimenopausal syndrome with HongHua XiaoYao Pill

Tongji hospital, Tongji Medical College of Huazhong University of Science and Technology0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•1. Healthy women aged 40-65;
•2. Menstrual disorders persist for more than 3 months, or amenorrhea within 2 to 12 months;
•3. Suffering from any of the following symptoms: vasomotor symptoms (hot flashes, sweating), somatic symptoms (insomnia, fatigue, headache, paresthesia), psychological symptoms (nervousness, depression) or genitourinary symptoms (dyspareunia) , vaginal dryness, urinary tract infection);
•4. Serum follicle stimulating hormone (FSH) > 10 IU/L, or decreased estradiol (E2)
•5. Have not received hormone replacement therapy or other drugs for perimenopausal symptoms in the past 2 months;
•6. The uterus and bilateral appendages are intact without resection;
•7. Sober and patients accept informed consent.

•1. Ovarian malignant tumor, premature ovarian failure, uterine fibroids =2cm, severe breast hyperplasia;
•2. Combined with gynecological acute infectious diseases or other acute infectious diseases;
•3. Severe liver and kidney dysfunction or other serious systemic diseases;
•4. Participated in other clinical trials;
•5. Patients who did not receive treatment as prescribed or who dropped out of the trial.

发起方

Tongji hospital, Tongji Medical College of Huazhong University of Science and Technology